Mouse Osteoprotegerin (TNFRSF11B) ELISA Kit

This Mouse Osteoprotegerin (TNFRSF11B) ELISA Kit from Innovative Research is intended for quantitative detection of mouse OPG in cell culture supernates, serum and plasma (EDTA). Strip well format. Reagents for up to 96 tests.

This mouse OPG ELISA Kit was based on standard sandwich enzyme-linked immune-sorbent assay technology. A monoclonal antibody from rat specific for OPG has been precoated onto 96-well plates. Standards(NSO, E22-L401) and test samples are added to the wells, a biotinylated detection polyclonal antibody from goat specific for OPG is added subsequently and then followed by washing with PBS or TBS buffer. Avidin-Biotin-Peroxidase Complex was added and unbound conjugates were washed away with PBS or TBS buffer. HRP substrate TMB was used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the mouse OPG amount of sample captured in plate.

• Detection Target: Osteoprotegerin (TNFRSF11B)
• Uniprot ID: O08712)
• Reactivity: Mouse
• Cross-Reactivity: There is no detectable cross-reactivity with other relevant proteins.
• Range: 93.7pg/ml-6000pg/ml
• Sensitivity: <5pg/ml
• Storage Conditions: Store at 4?C for 6 months, at -20?C for 12 months. Avoid multiple freeze-thaw cycles. (Shipped with wet ice)

Additional Information: The capture antibody is a monoclonal antibody from rat, the detection antibody is a biotinylated polyclonal antibody from goat. Expression system for standard: Osteoprotegerin(OPG) is identical to osteoclastogenesis inhibitory factor(OCIF), a soluble member of the tumor-necrosis factor receptor family that inhibits osteoclastogenesis. OPG is considered to play an important role in the regulation of bone resorption by modifying osteoclast differentiation. Osteoprotegerin is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease. It can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity. OPG system may play a critical role in the development of osteolytic bone disease in multiple myeloma and that targeting this system may have therapeutic potential. OPG also plays a role in the vascular system.; Immunogen sequence: 380